Drug intelligence / Profile preview

FreAmine III

Development stage
Unknown
Lead developer
B. Braun
Modality
Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
Administration
Intravenous
01

Overview

FreAmine III is a sterile, nonpyrogenic amino acid injection used for parenteral nutrition to provide a balanced mixture of essential and nonessential amino acids for protein synthesis and nitrogen balance support in adults, typically administered with dextrose and/or fat emulsion as part of total parenteral nutrition. It is available as 10% amino acid solution and as lower-strength formulations with electrolytes; the 10% product provides 15.3 g nitrogen and 97 g amino acids per 1000 mL, with L-amino acids except glycine, and is hypertonic (calculated osmolarity ~950 mOsm/L). Mechanistically, the amino acids serve as substrates for protein synthesis, spare body protein, and support anabolism when adequate calories are provided. B. Braun Medical is the NDA holder/manufacturer in the U.S.; historical and international presentations also exist. Indications include prevention of nitrogen loss or treatment of negative nitrogen balance as part of parenteral nutrition regimens, with dosing individualized by nitrogen balance and clinical response.[1][3][4][5][2]

Brand names
FreAmine III
Other names
10% FreAmine III Amino Acid InjectionFreAmine III with ElectrolytesFreAmine III 8.5% with Electrolytes

Beyond the preview

Go deeper on FreAmine III.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on FreAmine III.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call